Benzinga | Mar 18, 2021 08:50AM EDT

Citigroup Maintains Buy on Horizon Therapeutics, Announces $120 Price Target

Citigroup analyst Navann Ty maintains Horizon Therapeutics (NASDAQ:HZNP) with a Buy and announces $120 price target.